Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Study Summary

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).

Conditions

Peripheral T-Cell Lymphoma, Not Otherwise Specified Angioimmunoblastic T-cell Lymphoma Follicular T-Cell Lymphoma Nodal Peripheral T-Cell Lymphoma With TFH Phenotype Systemic Anaplastic Large Cell Lymphoma Lymphoma, T-Cell, Peripheral Lymphoma, T-Cell

Interventions / Drugs

Soquelitinib Belinostat Pralatrexate

View on ClinicalTrials.gov ↗

Sponsor

CRVS

Corvus Pharmaceuticals

Oncology

D49/100

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorCorvus Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:10:54.089228+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.